The World's Most Reliable Superpharma AI
96% ex-ante
clinical prediction accuracy
Trusted by Top 20 Big Pharma Companies and Top 5 Institutional Investors
Having been adopted to enhance and derisk 200+ billion USD healthcare portfolio, BioinvestGPT is the world's only super-reliable clinical AI featuring two million human-equivalent virtual patients that predict clinical benefits in days for any-stage novel medicine and every human disease with 96% ex-ante accuracy and clear rationale.
Superpharma Use Cases
BioinvestGPT help partners shift from a “fail often and fail late” old paradigm to a “succeed often and succeed early” new reality with multiple use cases:
03
I’m a paragraph. Double click me or click Edit Text, it's easy.
Use Case 2
Merge & Acquisition Screening
Glittering like morning dew before evaporating with the rise of the sun, bio first-in-class M&As have long been risky endeavors with only a 30% success rate for decades.
With a proven track record of achieving a 90% success rate in both GO/NO-GO M&A decisions, BioinvestGPT could generate hundred-billion-dollar value for big pharma companies.
In 2024, BioinvestGPT could have saved big pharma companies such as Novo Nordisk (1682), AbbVie (1457, 1458), and Incyte (1575, 1584) at least $12 billion in cash that evaporated due to the negative clinical readouts of their recently acquired assets, all of which had been accurately predicted by BioinvestGPT’s virtual clinical trials 6-9 months in advance with compelling timestamped proof and clear actionable rationale.
Use Case 3
Indication Expansion
BioinvestGPT has a compelling track record of exhaustively identifying clinically meaningful indications for FIC/BIC assets across all the major therapeutic areas.
For GLP1R agonists, BioinvestGPT maintains 100% ex-ante prediction accuracy for all the indication expansion clinical trials of Semaglutide and Tirzapertide: Alzheimer's Disease (1520, 1521), NASH (1513, 1523), HFpEF (1512, 1684), Knee Osteoarthritis (1272), MACE (973, 1519), Diabetic Eye Diseases and T2DM (1534), Heart Disease with T2DM (1532), Peripheral Arterial Disease and T2DM (1531), Heart Failure (1525, 1526), Chronic Kidney Diseases (1515, 1524), Obstructive Sleep Apnea (716), in addition to Obesity (992, 1517, 1518, 687, 1514).
Use Case 4
Use Case 4
Competitive Analysis
BioinvestGPT virtual patients are proven to differentiate competing drug candidates via head-to-head virtual clinical trials that dynamically rank their comparative clinical benefits.
For example, BioinvestGPT’s metabolic disorder virtual patients have maintained 100% ex-ante clinical benefit prediction accuracy when it comes to running head-to-head virtual clinical trials and ranking all the clinical-stage anti-obesity FIC/BIC assets (MariTide, CagriSema, S309309, monlunabant, semaglutide, tirzepatide, VK2735, CT996, GSBR1290, ZP8396, TERN601, danuglipron, amycretin, orforglipron, AZN5004, etc.) in terms of efficacy, tolerability, muscle preservation, cardio protection, and possibly any other yet-to-be-investigated endpoints/indications.
